DRG Market Assessment 보고서

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Pirfenidone was the first disease-modifying therapy (DMT) approved for IPF,…

Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in that country by 2033. Treatment of metastatic disease is dominated by…

Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in that country by 2033. Treatment of metastatic disease is dominated by…

The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) continues to fragment as newer entrants in established classes such as TG Therapeutics’ Briumvi, Novartis’s Kesimpta,…

Clarivate Epidemiology’s coverage of peripheral arterial disease (PAD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PAD…

The renal cell carcinoma (RCC) treatment landscape in China has evolved rapidly since the introduction of targeted therapies, including TKIs (Pfizer’s Sutent and Inlyta, Novartis’s Votrient,…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key PAD patient populations, covering 171 countries and more than 99% of…

Clarivate Epidemiology’s coverage of PAD comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total prevalence of PAD for each country, as…

Clarivate Epidemiology’s coverage of uterine fibroids comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

The treatment of prostate cancer in China is undergoing a transformative phase, characterized by an increase in diagnosed incident cases due to improved screening techniques. This shift is…

Clarivate Epidemiology’s coverage of chronic daily headache (CDH) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

CAR T-cell therapies, such as Gilead / Kite Pharma’s Yescarta and Johnson & Johnson Innovative Medicine’s Carvykti, have given hope to patients with relapsed/refractory (R/R) non-Hodgkin’s…